Press Releases Latest May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting Press Releases Year None202420232022202120202019201820172016201520142013 Sep 03, 2014 Theratechnologies resumes distribution of EGRIFTA® (Tesamorelin for injection) in the United States Jul 09, 2014 Theratechnologies Announces Financial Results for Second Quarter of 2014 Jun 25, 2014 Theratechnologies to receive 4.1 million dollar payment from Revenue Canada Jun 10, 2014 Theratechnologies Obtains U.S. Patent Term Extension for Tesamorelin May 23, 2014 Additional Update on Availability of EGRIFTA® (tesamorelin for injection) in the United States May 21, 2014 Announcements in Conjunction With Theratechnologies Annual Meeting May 20, 2014 Update on Availability of EGRIFTA™ in the United States May 01, 2014 Theratechnologies regains rights to EGRIFTA (tesamorelin for injection) in the United States Apr 30, 2014 Health Canada approves EGRIFTA Apr 14, 2014 Theratechnologies announces financial results for first quarter of 2014 First page « Previous page ‹ … Page 29 Page 30 Page 31 Page 32 Current page 33 Page 34 Page 35 Page 36 Page 37 Next page › Last page » Displaying 321 - 330 of 361
May 02, 2024 Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
Sep 03, 2014 Theratechnologies resumes distribution of EGRIFTA® (Tesamorelin for injection) in the United States
May 23, 2014 Additional Update on Availability of EGRIFTA® (tesamorelin for injection) in the United States
May 01, 2014 Theratechnologies regains rights to EGRIFTA (tesamorelin for injection) in the United States